Breaking: Novo Nordisk CEO to step down as company seeks turnaround

Lars Fruergaard Jørgensen led the company as it rode the boom of its obesity and diabetes drugs, only to see that success stall recently.

Log In    Subscribe BREAKING NEWS   Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround By Andrew Joseph LUDOVIC MARIN/POOL/AFP via Getty Images Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the biggest players in pharma, only to see that success stall in recent months, is stepping down as CEO, the company said Friday. READ MORE Sign up for The Readout Your morning rundown of the science, politics, and money driving biotech today. Learn more. In Case You Missed It 1   Novo Nordisk strikes deal with Septerna to develop obesity pills By Elaine Chen 2   The end of compounded GLP-1 copies leaves many patients in a 'lose-lose' position By Katie Palmer and Elaine Chen 3   Eli Lilly shares fall as competitor Novo notches coverage win for obesity drug By Elaine Chen 4   CRISPR is used in landmark treatment to correct genetic misspelling of a single patient By Jason Mast Get your first 3 months for $30 Unlock access to STAT's award-winning journalism, premium data tools, and must-read, subscriber-only newsletters. Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us